Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is bullish on the stock heading into Phase 3 Origin results in IgAN expected ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks ...

After hours: February 3 at 5:26:14 PM EST Loading Chart for VERA ...

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company ...